

November 12, 2021

Name of listed company: Chugai Pharmaceutical Co., Ltd.  
Code number: 4519 (1<sup>st</sup> Section of Tokyo Stock Exchange)  
Head office: 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo  
President & CEO: Osamu Okuda  
Inquiries to: Toshiya Sasai  
Head of Corporate Communications Dept.  
Tel: +81-(0)3-3273-0554

## **Atea Announces Update of Clinical Studies Evaluating AT-527 for COVID-19 in the Outpatient Setting**

[Chugai Pharmaceutical Co., Ltd.](#) announced that Atea issued a press release on November 11 regarding update of MOONSONG study and MORNINGSKY study evaluating the RNA polymerase inhibitor AT-527 for COVID-19 in the outpatient setting.

Please refer to the link below for details of the press release:

Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Third Quarter 2021 Financial Results

<https://ir.ateapharma.com/news-releases/news-release-details/atea-pharmaceuticals-provides-clinical-and-corporate-update-0>

###